MHIF Celebrates Major Research Milestone for Patients

Image

The Minneapolis Heart Institute Foundation (MHIF) is proud to celebrate a significant research milestone that reflects our continued commitment to advancing cardiovascular care. Our leadership in the LEADR clinical trial contributed directly to the recent regulatory approval of Medtronic’s newly approved OmniaSecure™ ICD lead.

Allina Health Minneapolis Heart Institute was not only among the first sites to enroll patients in the OmniaSecure global clinical trial, but is also the first center in the Upper Midwest to offer this innovative technology commercially to patients. Congratulations to Drs. Kris Krueger, John Zakaib, Matt Olson, and R. Dent Underwood, along with the entire MHIF research team, for their outstanding work and dedication.

The OmniaSecure lead represents a major advancement in implantable cardioverter‑defibrillator therapy. At 64% smaller than traditional defibrillation leads, it is designed to reduce anatomical disruption and enhance the long-term patient experience. This is a great example of how research advances care and options for patients.